TY - JOUR
T1 - A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors
AU - Hong, D. S.
AU - Kurzrock, R.
AU - Naing, A.
AU - Wheler, J. J.
AU - Falchook, G. S.
AU - Schiffman, J. S.
AU - Faulkner, N.
AU - Pilat, M. J.
AU - O'Brien, J.
AU - LoRusso, P.
N1 - Funding Information:
Conflicts of interest D. S. Hong received research grant funding from Eisai for this study. J. O’Brien is affiliated with Eisai Inc., NJ, USA. The remaining authors have no conflicts of interest to declare.
Funding Information:
Acknowledgments We gratefully acknowledge the participating patients, their families, and study investigators for their invaluable contribution. Editorial support was provided by Deborah McGregor, PhD, of Complete Medical Communications, funded by Eisai Inc., and Jo Ann of the Department of Investigational Cancer Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, Texas. This study was funded by Eisai Inc.
PY - 2014/6
Y1 - 2014/6
N2 - The aim of this study was to determine the maximum tolerated dose, dose-limiting toxicities, and pharmacokinetic profile of E7107 in patients with advanced solid tumors. Patients in this phase I, open-label, single-arm, dose-escalation study had metastatic or locally advanced solid tumors and received E7107 as a 30-minute intravenous infusion at doses of 0.6, 1.2, 1.8, 2.4, 3.2, 4.3, and 5.7 mg/m2. Twenty-six patients were enrolled in the study. At 5.7 mg/m2, two patients experienced dose-limiting toxicities including diarrhea, vomiting, dehydration, and myocardial infarction on Days 1-3 following E7107 administration. Three additional patients were recruited at the lower dose and all six patients tolerated E7107 4.3 mg/m 2 with no dose-limiting toxicities. The maximum tolerated dose of E7107 was therefore 4.3 mg/m2. The most common drug-related adverse events were nausea, vomiting, and diarrhea. Vision loss was experienced by two patients at Cycles 2 and 7, each patient receiving 3.2 mg/m2 and 4.3 mg/m2, respectively. This resulted in the study being put on clinical hold. Pharmacokinetic analysis showed that E7107 was rapidly distributed with a moderate elimination half-life (6-13 h) and high clearance. Exposure to E7107 was dose-related. The best tumor response was stable disease in eight patients. E7107 is a unique first-in-class molecule. The incidence of two cases of vision loss probably related to E7107 led to study discontinuation.
AB - The aim of this study was to determine the maximum tolerated dose, dose-limiting toxicities, and pharmacokinetic profile of E7107 in patients with advanced solid tumors. Patients in this phase I, open-label, single-arm, dose-escalation study had metastatic or locally advanced solid tumors and received E7107 as a 30-minute intravenous infusion at doses of 0.6, 1.2, 1.8, 2.4, 3.2, 4.3, and 5.7 mg/m2. Twenty-six patients were enrolled in the study. At 5.7 mg/m2, two patients experienced dose-limiting toxicities including diarrhea, vomiting, dehydration, and myocardial infarction on Days 1-3 following E7107 administration. Three additional patients were recruited at the lower dose and all six patients tolerated E7107 4.3 mg/m 2 with no dose-limiting toxicities. The maximum tolerated dose of E7107 was therefore 4.3 mg/m2. The most common drug-related adverse events were nausea, vomiting, and diarrhea. Vision loss was experienced by two patients at Cycles 2 and 7, each patient receiving 3.2 mg/m2 and 4.3 mg/m2, respectively. This resulted in the study being put on clinical hold. Pharmacokinetic analysis showed that E7107 was rapidly distributed with a moderate elimination half-life (6-13 h) and high clearance. Exposure to E7107 was dose-related. The best tumor response was stable disease in eight patients. E7107 is a unique first-in-class molecule. The incidence of two cases of vision loss probably related to E7107 led to study discontinuation.
KW - Advanced solid tumors
KW - E7107
KW - Pharmacodynamic
KW - Pharmacokinetic
KW - Phase I
UR - http://www.scopus.com/inward/record.url?scp=84904635074&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904635074&partnerID=8YFLogxK
U2 - 10.1007/s10637-013-0046-5
DO - 10.1007/s10637-013-0046-5
M3 - Article
C2 - 24258465
AN - SCOPUS:84904635074
SN - 0167-6997
VL - 32
SP - 436
EP - 444
JO - Investigational New Drugs
JF - Investigational New Drugs
IS - 3
ER -